<DOC>
	<DOC>NCT02179359</DOC>
	<brief_summary>This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Anemia, Diamond-Blackfan</mesh_term>
	<mesh_term>Thrombasthenia</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Lipomatosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other nonmalignant hematologic disorders for which a stem cell transplant is indicated Acceptable stem cell source identified Performance status of ≥ 70% (Karnofsky),or ≥ 70 (Lansky play score) Creatinine &lt;2.0 mg/dl for adults or glomerular filtration rate &gt; 50 ml/min for children Bilirubin, Aspartate Aminotransferase, Alkaline phosphatase &lt;5 times the upper limit of institutional normal Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction &gt; 40% active, uncontrolled infection pregnant or breastfeeding HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stem Cell Transplant</keyword>
</DOC>